Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple SclerosisBusiness Wire • 05/05/22
Called to Account: Drug companies are making an accounting change after the SEC cracked down on BiogenMarket Watch • 05/03/22
Biogen Inc. (BIIB) CEO Michel Vounatsos on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/03/22
BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping DownInvestorPlace • 05/03/22
Biogen'a Q1 profit and revenue lag estimates, weighed down by Alzheimer's drugMarket Watch • 05/03/22
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)Business Wire • 05/02/22
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/26/22